News

Results are from the first stage of an ongoing phase III study of HuMax-CD4 in cutaneous T-cell lymphoma (CTCL) and an ongoing phase II study in non-cutaneous T-cell

Chemotherapy plus Biogen Idec's Rituxan is the emerging standard of care for this patient population. When added to the chemotherapy/Rituxan combination regimen, lumiliximab demonstrated a 52% complete response

Idraparinux is being developed as an alternative to standard treatment heparin, and can be taken less often than current medication. The researchers' primary measure of success was whether

Ceflatonin is for use in chronic myeloid leukaemia (CML) patients who have developed resistance to Gleevec and other tyrosine kinase inhibitors. Following treatment with the drug combination, 42%

Graft vs host disease, or GVHD, is a life threatening immunological reaction that occurs in certain patients who have received a bone marrow transplant. There are no approved

Paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening form of hemolytic anemia, is an acquired genetic blood disorder characterized by destruction of red blood cells by the body's

In the study patients receiving Aranesp were nearly three times more likely to achieve a hematopoietic response than patients receiving a placebo. “Patients with cancer who are not

Mantle cell lymphoma (MCL) is a relatively uncommon and aggressive form of non-Hodgkin’s lymphoma for which there was no standard of care in the relapsed or refractory setting.

We have a strong pipeline of new products in the FDA, additional new products coming through the development process, such as our troponin assay, but our marketing efforts